

Notification of IRB Approval/Activation

Protocol Number: CR-16-055

Date: 22/Apr/2016

To: ChangHyeong Lee

From: HyeOk Yu

33, Duryugongwon-ro 17gil, Namgu, Daegu, 42472, Korea

Title of Protocol: Primary hepatic neuroendocrine tumor

Version Date: NA

Sponsor: NA

IRB Review Type: Expedite Board Review

IRB Approval Date: 14/Apr/2016

IRB Expiration Date: 31/May/2016

This Project has been reviewed and approved by the DCUMC IRB.

During the review of this Project, the IRB specifically considered (i) the risks and anticipated benefits, if any, to subjects; (ii) the selection of subjects; (iii) the procedures for securing and documenting informed consent; (iv) the safety of subjects; and (v) the privacy of subjects and confidentiality of the data.

NOTES: The following documents were reviewed and approved by the IRB: Protocol Summary, Main Protocol, Consent Form, and Questionnaires/Instruments.

As Principal Investigator you are responsible for the following:

1. Submission in writing of any and all changes to this project (e.g., protocol, recruitment materials, consent form, study completion, etc.) to the IRB for review and approval prior to initiation of the change(s), except where necessary to eliminate apparent immediate hazards to the subject(s). Changes made to eliminate apparent immediate hazards to subjects must be reported to the IRB within 24 hours.
2. Submission in writing of any and all adverse event(s) that occur during the course of this project in accordance with the IRB's policy on adverse event reporting.

Chairman: Jeong Kyu Kim, MD, PhD Date: 22/Apr /2016

Daegu Catholic University Medical Center Institutional Review Board

Daegu Catholic University Medical Center

